Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Common Equity (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Common Equity for 12 consecutive years, with $41.6 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity fell 80.65% year-over-year to $41.6 million; the TTM value through Mar 2026 reached $41.6 million, down 80.65%, while the annual FY2025 figure was $64.6 million, 77.57% down from the prior year.
  • Common Equity hit $41.6 million in Q1 2026 for Syndax Pharmaceuticals, down from $64.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $554.2 million in Q4 2023 and bottomed at $41.6 million in Q1 2026.
  • Average Common Equity over 5 years is $321.5 million, with a median of $361.9 million recorded in 2022.
  • Year-over-year, Common Equity surged 69.9% in 2022 and then plummeted 80.65% in 2026.
  • Syndax Pharmaceuticals' Common Equity stood at $467.4 million in 2022, then increased by 18.56% to $554.2 million in 2023, then plummeted by 48.01% to $288.1 million in 2024, then crashed by 77.57% to $64.6 million in 2025, then crashed by 35.6% to $41.6 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $41.6 million, $64.6 million, and $115.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.